Argenx Gears Up for US Launch of Vyvgart, Awaiting EU Decision

Argenx Gears Up for US Launch of Vyvgart, Awaiting EU Decision

315962

Argenx Gears Up for US Launch of Vyvgart, Awaiting EU Decision

Argenx is working toward the commercial launch of Vyvgart (efgartigimod) — recently approved by the U.S. Food and Drug Administration (FDA) — to treat adults in the U.S. with generalized myasthenia gravis (gMG) who have the most common type of MG-driving antibody. Vyvgart currently is up for possible approval in the European Union and Japan for treating gMG patients. Argenx is expecting regulatory decisions to be issued this year. “We enter 2022 very excited about…

You must be logged in to read/download the full post.